DLK1 and adrenal cortex carcinoma: Importantly, we find that DLK1 is a key driver of chemoresistance in ACC through maintenance of adrenocortical differentiation and expression of the drug efflux protein ABCB1 (MDR1, P-glycoprotein) thereby demonstrating an important biological function for this new immunotherapeutic target.